Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Phosphodiesterase Type 5 (PDE5) Inhibitor (Erectile Dysfunction)

Avanafil

Brand names: Spedra

Avanafil is an oral phosphodiesterase type-5 (PDE5) inhibitor used in the treatment of erectile dysfunction.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively inhibits PDE5, increasing cyclic GMP in the corpus cavernosum and enhancing nitric-oxide-mediated smooth muscle relaxation and penile blood flow in response to sexual stimulation.

Prescribing in practice

  • Contraindicated with any form of nitrate or nitric-oxide donor because concomitant use causes potentially life-threatening hypotension.
  • Use with caution and at reduced exposure with alpha-blockers and other antihypertensives owing to additive blood-pressure-lowering effects.
  • Avoid or adjust with potent CYP3A4 inhibitors, which markedly increase avanafil exposure.

Monitoring

No routine laboratory monitoring is required; assess cardiovascular fitness for sexual activity and response to treatment clinically.

Counselling the patient

  • Take before anticipated sexual activity; an erection still requires sexual stimulation to occur.
  • Seek urgent medical attention for an erection lasting several hours or for sudden visual or hearing loss.

Evidence & guidelines

Efficacy in erectile dysfunction is established in randomised controlled trials and reflected in the SPC.

Reference: NICE CKS Erectile dysfunction (2023); EAU Guidelines on Sexual and Reproductive Health (2024); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways